1999
Needle-exchange attendance and health care utilization promote entry into detoxification
Strathdee S, Celentano D, Shah N, Lyles C, Stambolis V, Macalino G, Nelson K, Vlahov D. Needle-exchange attendance and health care utilization promote entry into detoxification. Journal Of Urban Health 1999, 76: 448-460. PMID: 10609594, PMCID: PMC3456698, DOI: 10.1007/bf02351502.Peer-Reviewed Original ResearchConceptsUninfected injection drug usersInjection drug usersNeedle exchange programsNeedle exchange attendanceDrug abuse treatmentHospital admissionDrug usersHuman immunodeficiency virus testAbuse treatmentImportant public health goalHIV-seronegative subjectsHealth care utilizationOutpatient medical careHealth care providersRecent drug usePublic health goalsIndependent predictorsCare utilizationHIV serostatusDetoxification admissionsCare providersVirus testHIVNeedle exchangeDrug use
1996
Human Immunodeficiency Virus Infection and Infective Endocarditis among Injecting Drug Users
Manoff S, Vlahov D, Herskowitz A, Solomon L, Munoz A, Cohn S, Willoughby S, Nelson K. Human Immunodeficiency Virus Infection and Infective Endocarditis among Injecting Drug Users. Epidemiology 1996, 7: 566-570. PMID: 8899380, DOI: 10.1097/00001648-199611000-00002.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionHIV-seropositive subjectsImmunodeficiency virus infectionInfective endocarditisDrug usersCD4 cellsOdds ratioVirus infectionHistory of endocarditisRisk of endocarditisHIV-seronegative subjectsInjection drug useInjecting Drug UsersCase-control studyConditional logistic regressionRace/ethnicitySubsequent endocarditisOngoing cohortHIV infectionSerious complicationsHIV serostatusEnrollment dateLast visitCohort enrollmentEndocarditis cases
1995
Instability of Delayed-type Hypersensitivity Skin Test Anergy in Human Immunodeficiency Virus Infection
Caiaffa W, Graham N, Galai N, Rizzo R, Nelson K, Vlahov D. Instability of Delayed-type Hypersensitivity Skin Test Anergy in Human Immunodeficiency Virus Infection. JAMA Internal Medicine 1995, 155: 2111-2117. PMID: 7575072, DOI: 10.1001/archinte.1995.00430190107015.Peer-Reviewed Original ResearchConceptsHIV-seropositive subjectsHIV-seronegative subjectsCD4 cell countSkin test resultsDrug usersCell countDTH anergyDTH positivityDelayed-type hypersensitivity (DTH) skin testDelayed-type hypersensitivity anergyHuman immunodeficiency virus (HIV) infectionDTH skin testingSkin test anergyImmunodeficiency virus infectionCommunity-based cohortHuman immunodeficiency virusHypersensitivity skin testsCandida albicans antigenAnergy testingSerial skinCD4 cellsHIV statusSingle testSkin testingImmunodeficiency virus
1994
Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users.
Caiaffa W, Vlahov D, Graham N, Astemborski J, Solomon L, Nelson K, Muñoz A. Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users. American Journal Of Respiratory And Critical Care Medicine 1994, 150: 1493-1498. PMID: 7952605, DOI: 10.1164/ajrccm.150.6.7952605.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsCocaineCohort StudiesCrack CocaineFemaleHIV SeronegativityHIV SeropositivityHIV-1HumansImmunocompromised HostIncidenceMaleMarijuana SmokingOdds RatioPneumoniaPneumonia, PneumocystisRisk FactorsSmokingSubstance Abuse, IntravenousSubstance-Related DisordersConceptsInjection drug usersPneumocystis carinii pneumoniaHIV-seropositive injection drug usersBacterial pneumoniaOdds ratioCarinii pneumoniaCigarette smokingFirst episodeDrug usersIllicit drugsSeropositive injection drug usersCD4 lymphocyte countHIV-seronegative subjectsMedical record reviewHuman immunodeficiency virusCells/Conditional logistic regressionSeronegative subjectsCohort studyLymphocyte countRecord reviewImmunodeficiency virusControl subjectsRisk factorsUnivariate analysisPreparations for AIDS vaccine trials. Incident human immunodeficiency virus (HIV) infections in a cohort of injection drug users in Baltimore, Maryland.
Nelson K, Vlahov D, Galai N, Astemborski J, Solomon L. Preparations for AIDS vaccine trials. Incident human immunodeficiency virus (HIV) infections in a cohort of injection drug users in Baltimore, Maryland. AIDS Research And Human Retroviruses 1994, 10 Suppl 2: s201-5. PMID: 7865301.Peer-Reviewed Original ResearchConceptsInjection drug usersHIV incidenceIncident human immunodeficiency virus (HIV) infectionsDrug usersHIV vaccine trial participationHuman immunodeficiency virus (HIV) infectionRisk behaviorsCohort of IDUsHuman immunodeficiency virus (HIV) vaccinesHIV-seronegative subjectsHigh HIV incidenceImmunodeficiency virus infectionAIDS vaccine trialsVaccine trial participationImmunodeficiency virus vaccinesHigh-risk behaviorsHIV seroconversionAnnual incidenceHIV vaccineNeedle sharingTrial participationVaccine trialsVirus vaccineVirus infectionStudy subjects